Farrow Jeffrey S sold $877K of TARS

Farrow Jeffrey S (See Remarks) sold 14,396 shares of Tarsus Pharmaceuticals, Inc. (TARS) at $60.95 ($0.88M total) on 2026-06-16.

Original reporting
SEC EDGAR · Farrow Jeffrey S
Published Jun 17, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TARS
Bearish
medium confidence
Mentioned
$TARS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TARSBearishLow
01

Why it matters

The newest fact is the disclosed open-market sale by an officer (Jeffrey S. Farrow) on 2026-06-16, with holdings after the sale of 56,801 shares.

02

Market read

Traders may briefly reassess sentiment around TARS due to officer selling, but there is no new operational or financial guidance information.

03

What to watch

The filing lacks context on total compensation, prior holdings, and whether other insiders are selling/buying around the same period; traders may overinterpret a single sale.

Relevance 5/10Novelty 6/10Timing: Filed 2026-06-17; sale dated 2026-06-16

Background

The article is an SEC Form 4 insider transaction disclosure for Tarsus Pharmaceuticals, Inc.

Company-level read

Ticker impact

$TARSBearishMedium confidence
Context

SEC Form 4 shows officer Jeffrey S. Farrow sold 14,396 TARS shares on 2026-06-16 at $60.95/share for ~$877K, no 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless follow-on selling or other news emerges.

Evidence & confidence

The filing is primary-source and time-stamped, but the article provides only a routine insider sale size/value and no accompanying company-specific operational or guidance change.

Market effects

Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical/financing signal.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; absence of a 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • Tarsus Pharmaceuticals, Inc.

    Subject of the SEC Form 4 insider sale disclosure.

  • Jeffrey S. Farrow

    Officer who sold 14,396 shares on 2026-06-16 at $60.95/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TARSHighAI 8/10

Tarsus (TARS) Q3 2026 Earnings Call Transcript

Tarsus (TARS) reported Q3 2026 net product sales of $194.6M for XDEMVY, up 64% YoY. The company raised full-year sales guidance to $715M-$730M. Key growth drivers include increased patient demand, broader ECP prescribing, and retreatment. Tarsus also discussed pipeline progress and acquisition integration.

$TARSMedAI 8/10

Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals (NASDAQ:TARS) increased its 2026 XDEMVY sales outlook to $715M-$730M, citing stronger demand and advertising returns. Q3 saw 20% sequential growth in high-prescribing eye care professionals. The company expects 2027 direct-to-consumer spending of $80M-$95M. Gross margin is projected at 93%, with SG&A and R&D expenses outlined. Pipeline updates include TP-03 launch in China and upcoming trials for TP-04, TP-05, and IRX-101.